Browse the evidence

Post-exercise amino acid availability is less effective than insulin at inhibiting muscle protein breakdown (MPB); insulin secretion is primarily stimulated by glucose availability.

To maximize muscle retention after a workout, don't just rely on protein. Consuming carbohydrates alongside protein stimulates insulin, which is highly effective at suppressing muscle breakdown (MPB), potentially more so than amino acids alone in this specific context.

Dietary restriction stimulates neurogenesis (the generation of new neurons) in the adult hippocampus, primarily by enhancing the survival of newly generated cells via BDNF, rather than increasing the proliferation rate of stem cells.

Fasting or caloric restriction helps the brain create and keep new neurons in the hippocampus, which is linked to better memory and learning. This happens because the new neurons are more likely to survive, not because they are created faster. This benefit depends on having normal levels of BDNF.

Overexpression of TORC family proteins (TORC1, TORC2, TORC3) induces PGC-1α transcription and mitochondrial biogenesis in muscle cells, leading to increased mitochondrial oxidative capacity and fatty acid oxidation.

This research identifies TORC proteins as key switches that turn on mitochondrial growth in muscle. While you cannot directly 'dose' TORC, this mechanism explains why activities that trigger calcium and cAMP signaling (like exercise and cold exposure) are effective at building mitochondrial density. To leverage this, engage in regular physical activity and consider cold exposure, as these stimuli activate the TORC-PGC-1α pathway.

Resveratrol extends lifespan in some model organisms (yeast, nematodes, fish) primarily through indirect mechanisms like SIRT1 activation and calorie restriction mimicry, rather than direct antioxidant action.

Resveratrol may offer longevity benefits in specific contexts (e.g., metabolic dysfunction), likely by mimicking calorie restriction via SIRT1 activation. However, it is not a direct antioxidant and its benefits in healthy humans are unproven. Prioritize calorie restriction and exercise, which robustly activate these same pathways.

Activation of the GIP receptor, but not the GLP-1 receptor, increases plasma resistin levels.

This finding suggests that GIP receptor activation specifically influences resistin levels, a marker associated with insulin resistance. This adds nuance to the understanding of how different incretin pathways affect metabolic health markers beyond glucose and weight.

Insulin is the primary regulator of human adipose tissue lipoprotein lipase (LPL) activity; insulin deficiency (as in untreated diabetes) significantly reduces LPL activity, while elevated insulin levels (as in obesity or post-prandial states) increase it.

Your body's ability to store fat in adipose tissue is directly controlled by insulin. When you are insulin-deficient (untreated diabetes), fat storage capacity (LPL) is low. When you have high insulin (obesity or after eating carbs), fat storage capacity increases. Managing insulin secretion through dietary carbohydrate intake is the lever to control this enzyme's activity.

Metformin lowers blood glucose in Type 2 Diabetes primarily through gut-based pharmacology (altering bile acid recirculation and gut microbiota to enhance GLP-1 secretion) rather than solely through AMPK activation in the liver and muscle.

Metformin's effectiveness in Type 2 Diabetes relies heavily on its interaction with your gut, not just your liver. It changes your bile acids and gut bacteria, which triggers the release of GLP-1, a hormone that helps control blood sugar. This is why taking it orally is crucial; injecting it bypasses this gut mechanism and is less effective.

Deficiency of Estrogen Receptor Beta (ERβ) in adipose tissue leads to increased body fat mass but improved systemic insulin sensitivity and glucose tolerance under high-fat diet conditions, mediated by enhanced PPARγ signaling.

This research suggests that the presence or absence of specific estrogen receptors (ERβ) in fat tissue dictates whether fat accumulation harms or helps metabolic health. While this is a genetic/mechanistic finding in mice and not a direct human intervention, it implies that simply reducing fat mass is not the only path to metabolic health; the hormonal environment of the fat tissue is critical.

High intra-abdominal fat (IAF) is the primary determinant of an atherogenic lipoprotein profile (increased triglycerides, LDL, ApoB; decreased HDL), whereas insulin resistance contributes independently only to VLDL cholesterol.

Focus on reducing visceral fat rather than just total body weight. Even if you are 'lean' by BMI, high abdominal fat (measurable by CT or inferred by waist circumference) is strongly linked to bad cholesterol profiles. Lifestyle changes that reduce visceral fat (caloric restriction, exercise) improve lipid profiles, likely by reducing IAF and improving insulin sensitivity.

Reduced GH/IGF-1 signaling protects against age-related diseases such as diabetes and cancer in both mice and humans with GH deficiency/resistance.

Humans with genetic GH deficiency are protected from diabetes and cancer, suggesting that lower GH/IGF-1 signaling might be protective. However, this comes with trade-offs like small stature. For the general population, this does not support GH supplementation for disease prevention, as excess GH may be harmful.

Reduced GH/IGF-1 signaling extends longevity in mice through mechanisms including enhanced stress resistance, reduced inflammation, and improved insulin signaling.

The longevity benefits of low GH/IGF-1 signaling in mice are driven by better stress resistance, less inflammation, and better insulin sensitivity. This suggests that lifestyle factors improving these metrics (e.g., exercise, diet) may mimic some benefits of genetic deficiency.

Testosterone is the primary anabolic hormone responsible for skeletal muscle hypertrophy and strength gains, acting through genomic and non-genomic signaling pathways, whereas acute exercise-induced testosterone spikes are not the primary driver of these adaptations.

Focus on consistent resistance training and overall health rather than trying to manipulate acute hormonal spikes. Testosterone's role is foundational; if you have clinically low levels, medical intervention may be necessary, but for healthy individuals, the focus should be on the training stimulus and recovery, not chasing acute hormonal changes.

Growth Hormone (GH) assay choice significantly impacts the interpretation of exercise-induced GH responses, with bioassays detecting much higher concentrations than immunoassays due to the presence of bioactive GH aggregates.

For most exercisers, this is a research note. However, it suggests that standard blood tests for GH may not fully capture the body's anabolic response to exercise. Do not rely on single GH blood draws to judge training effectiveness.

Statin therapy induces skeletal muscle toxicity and atrophy by upregulating the muscle-specific ubiquitin ligase atrogin-1/MAFbx, which mediates increased protein breakdown via the ubiquitin-proteasome pathway.

If you experience muscle pain or weakness while taking statins, it may not be 'in your head' but a specific biological response involving muscle breakdown proteins (atrogin-1). Do not simply stop the medication without consulting your doctor. Discuss testing for muscle enzymes (CK) and potential strategies to mitigate this, such as CoQ10 supplementation or switching to a less lipophilic statin, as the paper suggests these mechanisms are linked to mitochondrial function and specific gene expression.

Obesity-associated leptin resistance, driven by impaired BBB transport and intracellular signaling inhibition (PTP1B/SOCS3), contributes to cognitive decline and Alzheimer's disease pathology by disrupting synaptic plasticity and memory formation.

For those with obesity or aging-related cognitive concerns, addressing metabolic health is critical for brain health. The paper suggests that the failure of leptin signaling (leptin resistance) is a key driver of cognitive decline, not just high leptin levels. Interventions that improve metabolic health may help restore leptin sensitivity and protect against cognitive decline.

Adiponectin exerts neuroprotective effects by enhancing synaptic plasticity (LTP), reducing neuroinflammation, and improving insulin sensitivity, with low levels in obesity contributing to cognitive risk.

Maintaining healthy adiponectin levels through weight management and exercise is beneficial for brain health. Adiponectin helps reduce inflammation and improve insulin sensitivity in the brain, which supports memory and protects against cognitive decline.

Overweight males exhibit higher fasting and postprandial GLP-1 concentrations compared to lean males, yet this hormonal difference does not translate to a difference in subjective appetite ratings or actual energy intake.

If you are overweight, your body may produce more GLP-1 (a satiety hormone) after eating than a lean person, but this doesn't automatically make you feel fuller or eat less. This suggests your body might be less sensitive to this specific signal. However, consuming protein preloads can still effectively reduce your subsequent food intake, just as it does for lean individuals.

Obstructive Sleep Apnea (OSA) independently exacerbates metabolic dysregulation (hypertriglyceridemia, hyperglycemia) and systemic inflammation (elevated C-reactive protein, uric acid) in patients with Metabolic Syndrome, regardless of the presence of daytime sleepiness.

If you have Metabolic Syndrome, you should be screened for Obstructive Sleep Apnea (OSA) even if you do not feel sleepy or snore loudly. Untreated OSA independently worsens your blood sugar, triglycerides, and inflammation. Treating OSA (e.g., with CPAP) may help improve these metabolic markers, so discuss sleep testing with your provider as part of your MetS management.

AMPK is required for exercise-mediated glucose uptake in skeletal muscle, as complete abolition of AMPK activity leads to dramatic reductions in glucose uptake during exercise.

AMPK plays a crucial role in how your muscles take up glucose during exercise. If AMPK activity is completely blocked, glucose uptake during exercise is significantly reduced. This highlights the importance of maintaining healthy AMPK function through regular physical activity.

Elevated malonyl-CoA levels in skeletal muscle inhibit fatty acid oxidation and promote lipogenesis, contributing to insulin resistance in obese and type 2 diabetic subjects.

In insulin-resistant individuals, high levels of malonyl-CoA block fat burning and promote fat storage in muscle, worsening insulin resistance. This is driven by low AMPK activity and high ACC activity. While this paper focuses on mechanism, it suggests that interventions restoring AMPK activity (like exercise or specific medications) may help reverse these defects.

Rosiglitazone treatment reverses elevated malonyl-CoA levels, restores fatty acid oxidation, and improves insulin sensitivity in type 2 diabetic subjects.

For type 2 diabetics, rosiglitazone (4mg twice daily for 3 months) was shown to normalize malonyl-CoA levels and restore fatty acid oxidation. This suggests that pharmacological intervention can correct specific muscle metabolic defects associated with insulin resistance.

In obese, hirsute women with hyperinsulinemia, metformin administration provides no additional benefit to androgen profiles or SHBG levels beyond what is achieved by a low-calorie, low-fat diet alone.

If you are obese and have hirsutism with high insulin, focus on a low-calorie, low-fat diet. Adding metformin will not improve your hormone levels (SHBG, testosterone) any more than the diet does on its own. You may avoid the medication and its side effects (like diarrhea) without losing hormonal benefits.

Intra-abdominal (visceral) fat contributes to insulin resistance through mechanisms including high lipolytic activity, direct portal delivery of fatty acids to the liver, and secretion of inflammatory cytokines, whereas subcutaneous fat (particularly gluteofemoral) is metabolically protective.

Focus on reducing abdominal fat rather than just total body weight. Visceral fat is metabolically active and harmful, while subcutaneous fat (especially on hips/thighs) is protective. Strategies that reduce visceral fat (like exercise and specific dietary patterns) are more effective for improving insulin sensitivity than those that only reduce total mass.

Intramyocellular triglyceride (IMTG) levels are not the direct cause of muscle insulin resistance; instead, active lipid intermediates like diacylglycerol (DAG) and ceramides are the likely culprits, explaining why insulin-sensitive athletes can have high IMTG.

High fat content in muscles (IMTG) does not automatically mean you are insulin resistant. The key is how that fat is broken down into active byproducts like DAG and ceramides. Exercise can increase IMTG while improving insulin sensitivity by promoting healthy lipid partitioning.